Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

Inclusion Criteria:

• All participants (Patients and Caregivers)-Table 1

• Age 18 or older

• Ability to read and respond in English

• Patient Inclusion Criteria (in addition to Table 1)

• Receiving care in the MGH Cancer Center

• Diagnosis of advanced (stage IV) melanoma or advanced, incurable lung cancer, including stage IV non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, extensive-stage small cell lung cancer.

• Plan to initiate immunotherapy with an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab or combination), per clinician documentation in the electronic health record or study staff communication with clinician

• Caregiver Inclusion Criteria (in addition to Table 1)

• Identified as "a supportive person involved in their cancer care" by a patient enrolled in the study

Exclusion criteria

• Major psychiatric condition or comorbid illness that prohibits participation in the study

• Cognitive impairment that prohibits provision of informed consent or participation in the study

• Pregnant women

• Prisoners